In vivo monoclonal antibody treatment with Ox19 (anti-rat CD5) causes disease relapse and terminates P2-induced immunospecific tolerance in experimental allergic neuritis
- 1 June 1989
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 23 (1) , 11-18
- https://doi.org/10.1016/0165-5728(89)90066-0
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- The LY‐1B Cell LineageImmunological Reviews, 1986
- Amplification of the immune response by agonistic antibodiesImmunology Today, 1986
- In Vivo Treatment of Rats with Monoclonal Anti‐T‐Cell AntibodiesScandinavian Journal of Immunology, 1985
- MRC OX‐19: A monoclonal antibody that labels rat T lymphocytes and augments in vitro proliferative responsesEuropean Journal of Immunology, 1984
- Prevention of experimental allergic neuritis in the lewis rat with bovine P2 proteinBrain Research, 1983
- Regulation of experimental allergic encephalomyelitis☆Part 4. Further characterization of postrecovery suppressor cellsJournal of Neuroimmunology, 1982
- Experimental Allergic Encephalomyelitis ‐ Susceptibility and SuppressionImmunological Reviews, 1981
- Two subsets of rat T lymphocytes defined with monoclonal antibodiesEuropean Journal of Immunology, 1980
- Experimental allergic neuritis in the Lewis rat: Characterization of the activity of peripheral myelin and its major basic protein,P2Brain Research, 1980
- Protective action of the encephalitogen and other basic proteins in experimental allergic encephalomyelitisImmunochemistry, 1968